CoChat

Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC

Open access

The DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.

Abstract

OBJECTIVES: The precipitous increase in nonalcoholic steatohepatitis (NASH) is accompanied by a dramatic increase in the incidence of NASH-related hepatocellular carcinoma (HCC). HCC in NASH has a higher propensity to arise without pre-existing cirrhosis compared with other chronic liver diseases. METHODS: To identify the potential links between liver and gut in NASH-related hepatocarcinogenesis, we compared the gut microbiota and mediators of bile acid (BA) signaling in the absence or presence of cirrhosis through the analysis of stool and serum samples from patients with NASH non-HCC and NASH-HCC and healthy volunteers. RESULTS: Serum levels of total and individual BA were higher in NASH compared with healthy controls. Furthermore, serum levels of the primary conjugated BAs glycine-conjugated cholic acid, taurine-conjugated cholic acid, glycine-conjugated chenodeoxycholic acid, and taurine-conjugated chenodeoxycholic acid were significantly increased in cirrhotic vs noncirrhotic patients, independent of the occurrence of HCC. By contrast, serum FGF19 levels were higher in patients with NASH-HCC and associated with tumor markers as well as an attenuation of BA synthesis. Specific alterations in the gut microbiome were found for several bacteria involved in the BA metabolism including Bacteroides and Lactobacilli. Specifically, the abundance of Lactobacilli was associated with progressive disease, serum BA levels, and liver injury in NASH and NASH-HCC. DISCUSSION: Here, we demonstrate a clear association of the altered gut microbiota and primary conjugated BA composition in cirrhotic and noncirrhotic patients with NASH-HCC. Microbiota-associated alterations in BA homeostasis and farnesoid X receptor signaling, via FGF19, might thus contribute to fibrogenesis, liver injury, and tumorigenesis in NASH-HCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.14309/ctg.0000000000000131

Cites

53 of 53 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1. Severity of the disease is associated with cell death, cirrhosis, and increased bile acid levels. Serum levels of cell death marker M65 (a) and apoptosis marker M30 (b) were increased stepwise in NASH-non-HCC and NASH-HCC as compared to controls. Fibrosis as assessed by liver stiffness measurement (LSM) by transient elastography/FibroScan (c) and NAFLD fibrosis score (d) reveal higher values in NASH-non-HCC and NASH-HCC while of course those individuals with biopsy proven cirrhosis showed higher levels. In patients with an NAFLD fibrosis score above 0.675, the presence of advanced liver fibrosis can be diagnosed with high accuracy. In patients with an NAFLD fibrosis score below −1.455, advanced liver fibrosis can be excluded with high accuracy. Scores between −1.455 and 0.676 are considered “indeterminate” (21). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NAFLD, nonalcoholic fatty liver disease; NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.
Figure 1. Severity of the disease is associated with cell death, cirrhosis, and increased bile acid levels. Serum levels of cell death marker M65 (a) and apoptosis marker M30 (b) were increased stepwise in NASH-non-HCC and NASH-HCC as compared to controls. Fibrosis as assessed by liver stiffness measurement (LSM) by transient elastography/FibroScan (c) and NAFLD fibrosis score (d) reveal higher values in NASH-non-HCC and NASH-HCC while of course those individuals with biopsy proven cirrhosis showed higher levels. In patients with an NAFLD fibrosis score above 0.675, the presence of advanced liver fibrosis can be diagnosed with high accuracy. In patients with an NAFLD fibrosis score below −1.455, advanced liver fibrosis can be excluded with high accuracy. Scores between −1.455 and 0.676 are considered “indeterminate” (21). Data are presented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NAFLD, nonalcoholic fatty liver disease; NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.CC BY · PubMed Central
Figure 2. Cirrhosis affects the regulation of bile acid metabolism. Total serum bile acids (a) and primary conjugated bile acids (c) showed a stepwise increase in NASH-non-HCC and NASH-HCC. Serum levels of 7-alpha-Hydroxy-4-Cholesten-3-one (C4) (b) were slightly increased in NASH-non-HCC patients but decreased in NASH-HCC patients. Serum levels of the FXR target molecule FGF19 (d) were increased in NASH-HCC patients with cirrhosis. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. FXR, farnesoid X receptor; NASH-HCC, non-alcoholic steatohepatitis-hepatocellular carcinoma.
Figure 2. Cirrhosis affects the regulation of bile acid metabolism. Total serum bile acids (a) and primary conjugated bile acids (c) showed a stepwise increase in NASH-non-HCC and NASH-HCC. Serum levels of 7-alpha-Hydroxy-4-Cholesten-3-one (C4) (b) were slightly increased in NASH-non-HCC patients but decreased in NASH-HCC patients. Serum levels of the FXR target molecule FGF19 (d) were increased in NASH-HCC patients with cirrhosis. Data are represented as mean ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. FXR, farnesoid X receptor; NASH-HCC, non-alcoholic steatohepatitis-hepatocellular carcinoma.CC BY · PubMed Central
Figure 3. Differences in diversity of bacterial communities in healthy vs NHc patients with distinctive changes on the phylum level. Phylotype richness, Shannon, and Simpson indexes diminished between groups, whereas the relative rarity index increased in N, NH, and NHc as compared to H and shown as median with range (a). Comparing healthy individuals and patients (e.g., here, the NHc group) the bacterial community was more homogenous in samples of healthy while NHc showed more diverse bacterial community. Stacked bar plot shows the means in microbial changes of abundances on the family level in H and NHc (b). Abundance of Bacteroidetes and Actinobacteria showed decrease from H to NHc, whereas abundances of Firmicutes and Proteobacteria did not reveal differences between the groups (c). Relative abundance of Fusobacteria was increased in N, Nc, NH, and NHc because of high abundances in single patients within these groups. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.
Figure 3. Differences in diversity of bacterial communities in healthy vs NHc patients with distinctive changes on the phylum level. Phylotype richness, Shannon, and Simpson indexes diminished between groups, whereas the relative rarity index increased in N, NH, and NHc as compared to H and shown as median with range (a). Comparing healthy individuals and patients (e.g., here, the NHc group) the bacterial community was more homogenous in samples of healthy while NHc showed more diverse bacterial community. Stacked bar plot shows the means in microbial changes of abundances on the family level in H and NHc (b). Abundance of Bacteroidetes and Actinobacteria showed decrease from H to NHc, whereas abundances of Firmicutes and Proteobacteria did not reveal differences between the groups (c). Relative abundance of Fusobacteria was increased in N, Nc, NH, and NHc because of high abundances in single patients within these groups. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001.CC BY · PubMed Central
Figure 4. Abundance of bacteria genera that modify bile acids is altered in NASH-non-HCC and NASH-HCC. Relative abundances of Bacteroides (a) and Bifidobacterium (b) were decreased, whereas Lactobacillus (c) and Ruminococcus (d) were increased from H to NHc. Relative abundance of Clostridium (e) and Escherichia/Shighella (f) did not differ between the groups. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.
Figure 4. Abundance of bacteria genera that modify bile acids is altered in NASH-non-HCC and NASH-HCC. Relative abundances of Bacteroides (a) and Bifidobacterium (b) were decreased, whereas Lactobacillus (c) and Ruminococcus (d) were increased from H to NHc. Relative abundance of Clostridium (e) and Escherichia/Shighella (f) did not differ between the groups. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.CC BY · PubMed Central
Figure 5. Taxonomic ranks that are related to Lactobacillus showed a progressive increase in abundance from healthy to cirrhotic NASH-HCC patients. The taxonomic ranks class (Bacilli, a), order (Lactobacillales, b), family (Lactobacillaceae, c), and phylotype (Phy60 Lactobacillus, d) showed a progressive increase of abundances from control to NHc. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.
Figure 5. Taxonomic ranks that are related to Lactobacillus showed a progressive increase in abundance from healthy to cirrhotic NASH-HCC patients. The taxonomic ranks class (Bacilli, a), order (Lactobacillales, b), family (Lactobacillaceae, c), and phylotype (Phy60 Lactobacillus, d) showed a progressive increase of abundances from control to NHc. Data are represented as median and plotting the individual patients in the graph. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001. NASH-HCC, nonalcoholic steatohepatitis-hepatocellular carcinoma.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 53 references

Cited by

See all 130

Metadata

Authors
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., Hohenester, S., Link, A., Faber, K. N., Moshage, H., Cubero, F. J., Friedman, S. L., Gerken, G., Trauner, M., Canbay, A., & Bechmann, L. P.
Affiliations
  • University Hospital Magdeburg (DE)
  • Essen University Hospital (DE)
  • Department of Gastroenterology, Hepatology, and Infectious Diseases, Otto von Guericke University Hospital Magdeburg, Magdeburg, Germany;
  • University of Cologne (DE)
  • LMU Klinikum (DE)
  • University Medical Center Groningen (NL)
  • Universidad Complutense de Madrid (ES)
  • Icahn School of Medicine at Mount Sinai (US)
  • Medical University of Vienna (AT)
  • Universitätsklinikum Knappschaftskrankenhaus Bochum (DE)
Corresponding author
Bechmann, Lars P.
Venue
Clinical and Translational Gastroenterology
Published
2020-03
Volume
11
Issue
3
Pages
e00131
ISSN
2155-384X (ISSN-L)
OpenAlex
W3009620456
Cited by
127
References
52
Citations by year
2026: 8 · 2025: 20 · 2024: 29 · 2023: 15 · 2022: 28 · 2021: 23 · 2020: 4
FWCI
5.68
Type
journal article
Language
en
Open access
Locations
  • Clinical and Translational Gastroenterology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Kölner Universitäts PublikationsServer (Universität zu Köln) (publishedVersion)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
  • Digitalen Hochschulbibliothek Sachsen-Anhalt (Universitäts- und Landesbibliothek Sachsen-Anhalt) (cc-by)
Funders
National Cancer Institute (P30CA196521)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
nonalcoholic steatohepatitis, hepatocellular carcinoma, liver cirrhosis, gut microbiota, bile acid signaling, FGF19, farnesoid X receptor, bile acid conjugates, lactobacilli, Bacteroides, liver injury, hepatocarcinogenesis, gut-liver axis
MeSH terms
Gastrointestinal Microbiome, Receptor, Farnesoid X-Activated, Adult, Aged, Bacteroides, Bile Acids and Salts, Feces, Female, Fibroblast Growth Factors, Carcinoma, Hepatocellular, Humans, Lactobacillus, Liver, Liver Cirrhosis, Liver Neoplasms, Male, Middle Aged, Signal Transduction, Case-Control Studies, Receptors, Cytoplasmic and Nuclear, Young Adult, Carcinogenesis, Healthy Volunteers, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. https://app.cochat.ai/papers/10.14309/ctg.0000000000000131
The paper
Sydor, S., Best, J., Messerschmidt, I., Manka, P., Vilchez-Vargas, R., Brodesser, S., Lucas, C., Wegehaupt, A., Wenning, C., Aßmuth, S., Hohenester, S., Link, A., Faber, K. N., Moshage, H., Cubero, F. J., Friedman, S. L., Gerken, G., Trauner, M., Canbay, A., & Bechmann, L. P. (2020). Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. Clinical and Translational Gastroenterology. https://doi.org/10.14309/ctg.0000000000000131

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.